LCP
MYGN icon

Lombardia Capital Partners’s Myriad Genetics MYGN Stock Holding History

Lombardia Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-15,487
Closed -$319K – 123
2016
Q3 		$319K Buy
+15,487
New +$393K 0.02% 164

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lombardia Capital Partners's MYGN Position: Q4 2016 in Review

Lombardia Capital Partners sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 15,487 shares — an estimated $319K sold.

Lombardia Capital Partners first reported a position in MYGN in Q3 2016 and held it in 1 quarter. The position peaked at $319K in Q3 2016. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Lombardia Capital Partners reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Lombardia Capital Partners sold 15,487 Myriad Genetics shares in Q4 2016, an estimated $319K.
  • Lombardia Capital Partners first reported a position in Myriad Genetics in Q3 2016 and held it in 1 quarter.
  • Lombardia Capital Partners's Myriad Genetics position peaked at $319K in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Lombardia Capital Partners's 13F filing for Q4 2016, filed 10 Feb 2017.